Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: Review of current algorithms

Therapeutic Drug Monitoring

Volumn 23, Issue 2, 2001, Pages 100-114

  David, Olivier J ^a   Johnston, Atholl ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Area under the curve; Cyclosporin; Forecasting method; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG MONITORING; HUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VALIDATION PROCESS;

ALGORITHMS; AREA UNDER CURVE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDICTIVE VALUE OF TESTS;

EID: 0035086787     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200104000-00003     Document Type: Article

References (102)

1. Cyclosporin microemulsion. A guide to usage and monitoring
2. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy
3. Cyclosporin blood levels do correlate with clinical complications
4. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients
5. Cyclosporine monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring
6. Prediction of acute graft rejection in renal transplantation: The utility of cyclosporine blood concentrations
7. Efficacy of area under the curve cyclosporine monitoring in renal transplantation
8. Do cyclosporin profiles provide useful information in the management of renal transplant recipients?
9. Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants
10. Challenges in cyclosporine therapy: The role of therapeutic monitoring by area under the curve monitoring
11. Impact of early cyclosporin average blood concentration on early kidney transplant failure
12. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
13. Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients
14. Blood concentrations and clinical effect of cyclosporin in psoriasis
15. The pharmacokinetics of Sandimmun Neoral: A new oral formulation of cyclosporine
16. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: Report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997)
17. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation
18. max) correlate with freedom from liver graft rejection: Results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)
19. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation
20. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation
21. A limited sampling strategy for the measurement of cyclosporine AUC
22. Limited sampling models for amonafide (NSC 308847) pharmacokinetics
23. Limited sampling model for vinblastine pharmacokinetics
24. A limited sampling strategy for cyclophosphamide pharmacokinetics
25. Abbreviated kinetic profiles in area-underthe-curve monitoring of cyclosporine therapy
26. Optimum numerical integration methods for estimation of area-under-the- curve (AUC) and area-under-the-momentcurve (AUMC)
27. Comparison of three methods for cyclosporine area under the curve monitoring calculations
28. Measuring cyclosporin AUC after Neoral using limited sampling strategy - Weighted or unweighted linear regression ?
29. Some suggestions for measuring predictive performance
30. A limited sampling strategy for the estimation of eight-hour Neoral areas under the curve in renal transplantation
31. Sparse-sampling-a practical method for measurement of AUCs
32. Statistical methods for assessing agreement between two methods of clinical measurement
33. Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients
34. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral
35. Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with Neoral
36. Abbreviated cyclosporine AUCs on Neoral - The search continues!
37. Improving the therapeutic monitoring of cyclosporin A
38. Cyclosporine monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure
39. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: Conversion study in stable renal transplant recipients
40. Abbreviating area under the curves further: A practical approach to monitoring extended pharmacokinetics with Neoral
41. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group
42. Clinically specific sparse sampling method for the evaluation of cyclosporine A (CyA) exposure in stable kidney transplantation
43. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy
44. Pharmacokinetic relationships of measured variables in children taking a new formulation of cyclosporin A
45. Abbreviated pharmacokinetic profiles in area-underthe-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral Study Group
46. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics
47. The pharmacokinetics of a new microemulsion of cyclosporine A (CyA) in pediatric kidney transplant patients
48. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals
49. Neoral kinetics in children treated with diltiazem
50. Predicting patients' exposure to cyclosporin
51. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations
52. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients
53. Cyclosporine A monitoring in children: Abbreviated area under curve formulas and C2 level
54. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral
55. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral
56. Prediction of cyclosporin area under the curve using a three-point sampling strategy after Neoral administration
57. Area under the concentration curve values in pediatric liver transplant recipients on cyclosporin microemulsion formulation
58. A limited sampling strategy for the estimation of 12-hour SangCya and Neoral AUCs in renal transplant recipients
59. A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients
60. Pharmacokinetics of cyclosporine microemulsion in Pakistani renal allograft recipients: Correlation of trough peak levels with 7-point and 3-point AUC
61. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients
62. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients
63. Preliminary pharmacokinetic evaluation of a new galenical formulation of oral cyclosporine A: Neoral
64. Validation of models for predicting area-under-the-curve in renal transplant patients receiving Neoral
65. Therapeutic monitoring of Cyclosporine-A in bone marrow transplantation - Past and present
66. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral)
67. Sparse sample measurement of cyclosporin AUC after Neoral in heart transplant patients
68. Therapeutic drug monitoring of cyclosporin A: Should we use the area under the concentration-time curve and forget trough levels?
69. Estimated areaunder-the-curve monitoring of Neoral in a stable pediatric renal transplant population: One-year experience
70. Abbreviated cyclosporine pharmacokinetic studies (CPKS) for management of Neoral dosing in pediatric renal transplant patients (RTP)
71. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients
72. Genetic ciclosporin withdrawn [Clinical Pharmacy]
73. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period
74. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period
75. Predicting cyclosporin AUC after Neoral. A comparison of published sparse sampling algorithms
76. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
77. Development of a general method of limited sampling for the determination of AUC for a drug that displays two-compartment pharmacokinetics
78. A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients
79. Relationship between area under the concentration versus time curve of cyclosporin A, creatinine clearance, hematocrit value, and other clinical factors in Japanese renal transplant patients
80. Bayesian estimation of cyclosporine clearance in bone marrow graft
81. Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by Bayesian and non-linear least squares methods
82. Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by means of total, lean and different adipose factors dosing body weight using Bayesian and nonlinear least squares methods
83. Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by one-, two- and three-compartment models using Bayesian and non-linear least squares methods
84. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting
85. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients
86. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation
87. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach
88. Effect of the number of samples on Bayesian and non-linear least-squares individualization: A study of cyclosporin treatment of haematological patients with multidrug resistance
89. Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: A population analysis in kidney transplant patients
90. Application of Bayesian forecasting to predict appropriate cyclosporine dosing regimens for renal allograft recipients
91. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients
92. A program for the optimization of cyclosporine therapy using population kinetics modeling
93. Gamma distribution of absorption times: Application to oral cyclosporine
94. Maximum a priori Bayesian estimation of oral cyclosporine pharmacokinetics in stable renal transplant patients
95. Physiologically based pharmacokinetics of cyclosporine A: Extension to tissue distribution kinetics in rats and scale-up to human
96. Pharmacokinetic validation of Neoral absorption profiling
97. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients
98. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period?
99. A 3-hour postdose cyclosporine level during the first week after kidney transplantation predicts acute rejection and cyclosporine nephrotoxicity more accurately than trough
100. Neoral absorption profiling: An evolution in effectiveness
101. New approaches to cyclosporine monitoring raise further concerns about analytical techniques
102. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring